Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

27.12 -0.48 (-1.74%)
Streaming Delayed Price Updated: 9:57 AM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Exelixis Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Phenomenal deals can still be found, even with the Nasdaq Composite climbing to a new all-time high. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the... 
Via Talk Markets
2 Biotech Stocks to Buy Hand Over Fist in March
These stocks are worth buying in most months of the year. 
Via The Motley Fool
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector. 
Via InvestorPlace
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
EXELIXIS INC (NASDAQ:EXEL) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
2 Stocks Under $30 to Buy and Hold
You don't need to be a millionaire to get started. Investing on a budget can work, too. 
Via The Motley Fool
Recap: Exelixis Q4 Earnings
Via Benzinga
Earnings Scheduled For February 6, 2024
Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion. 
Via Benzinga
Earnings Preview For Exelixis
Via Benzinga
4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Around $4M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
The 3 Best Biotech Stocks to Buy in February 2024
The best biotech stocks to buy offer consistent growth opportunities and resist the influence of singular drug successes. 
Via InvestorPlace
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals. 
Via Chartmill
4 Appealing Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
The growth-driven Nasdaq Composite hasn't put the 2022 bear market entirely in the rearview mirror, which means opportunistic investors can still find bargains. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
In the world of growth stocks, NASDAQ:EXEL shines as a value proposition.
NASDAQ:EXEL, a growth stock which is not overvalued. 
Via Chartmill
Breaking Down Exelixis: 7 Analysts Share Their Views
Via Benzinga
NASDAQ:EXEL is showing good growth, while it is not too expensive.
Don't overlook EXELIXIS INC (NASDAQ:EXEL)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
3 Attractive Medical Stocks To Buy After Earnings
Quite a few top-rated stocks have highlighted this week’s earnings lineup with now appearing to be an ideal time to buy. Following their favorable quarterly results, here are 3 intriguing healthcare... 
Via Talk Markets
Exelixis (EXEL) Q4 2023 Earnings Call Transcript
EXEL earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study
Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024
These top-rated biotech stocks are going to be in high demand in January and in every other month in 2024. 
Via InvestorPlace
6 Analysts Have This to Say About Exelixis
Via Benzinga
NASDAQ:EXEL, a growth stock which is not overvalued.
Investors seeking growth at a reasonable cost should explore NASDAQ:EXEL. 
Via Chartmill
3 Pharma Stocks Could Be the Pills Your Portfolio Needs
These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations. 
Via InvestorPlace
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut. 
Via Investor's Business Daily
Topics ETFs
Jim Cramer Likes This 'Well-Run' Airline, Says This Entertainment Stock Has 'Balance Sheet From Hell'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Franco-Nevada Corporation (NYSE: FNV) is a "great diversified 
Via Benzinga
Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation.
Investors should take note ofEXELIXIS INC (NASDAQ:EXEL), a growth stock that remains attractively priced. 
Via Chartmill
Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?
Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an  
Via Benzinga
Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance Woes
Shares of both skidded early Monday as the annual J.P. Morgan Healthcare Conferenced kicked off In San Francisco. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.